|
1
|
Institute of Medicine (US) Committee on
Preventing the Global Epidemic of Cardiovascular Disease, . Meeting
the Challenges in Developing CountriesFuster V and Kelly BB:
Promoting cardiovascular health in the developing world: A critical
challenge to achieve global health. National Academies Press;
Washington (DC): 2010
|
|
2
|
Evora PR, Nather J, Tubino PV, Albuquerque
AA, Celotto AC and Rodrigues AJ: Curbing inflammation in the
ischemic heart disease. Int J Inflam. 2013:1830612013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patzelt J, Verschoor A and Langer HF:
Platelets and the complement cascade in atherosclerosis. Front
Physiol. 6:492015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Diepenhorst GM, van Gulik TM and Hack CE:
Complement-mediated ischemia-reperfusion injury: Lessons learned
from animal and clinical studies. Ann Surg. 249:889–899. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Speidl WS, Kastl SP, Huber K and Wojta J:
Complement in atherosclerosis: Friend or foe? J Thromb Haemost.
9:428–440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Esser AF: The membrane attack complex of
complement. assembly, structure and cytotoxic activity. Toxicology.
87:229–247. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Francescut L, Steiner T, Byrne S,
Cianflone K, Francis S and Stover C: The role of complement in the
development and manifestation of murine atherogenic inflammation:
Novel avenues. J Innate Immun. 4:260–272. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Széplaki G, Varga L, Füst G and Prohászka
Z: Role of complement in the pathomechanism of atherosclerotic
vascular diseases. Mol Immunol. 46:2784–2793. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cubedo J, Padró T and Badimon L:
Coordinated proteomic signature changes in immune response and
complement proteins in acute myocardial infarction: The implication
of serum amyloid P-component. Int J Cardiol. 168:5196–5204. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mihlan M, Blom AM, Kupreishvili K, Lauer
N, Stelzner K, Bergström F, Niessen HW and Zipfel PF: Monomeric
C-reactive protein modulates classic complement activation on
necrotic cells. FASEB J. 25:4198–4210. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Giasuddin ASM, ElMahdawi JM and ElHassadi
FM: Serum complement (C3, C4) levels in patients with acute
myocardial infarction and angina pectoris. Bangladesh Med Res Counc
Bull. 33:98–102. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iltumur K, Karabulut A, Toprak G and
Toprak N: complement activation in acute coronary syndromes. APMIS.
113:167–174. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kostner KM, Fahti RB, Case C, Hobson P,
Tate J and Marwick TH: Inflammation, complement activation and
endothelial function in stable and unstable coronary artery
disease. Clin Chim Acta. 365:129–134. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yasuda M, Takeuchi K, Hiruma M, Iida H,
Tahara A, Itagane H, Toda I, Akioka K, Teragaki M, Oku H, et al:
The complement system in ischemic heart disease. Circulation.
81:156–163. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dobbin K and Simon R: Sample size
determination in microarray experiments for class comparison and
prognostic classification. Biostatistics. 6:27–38. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thygesen K and Alpert JS, Jaffe AS,
Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task
Force for Universal Definition of Myocardial Infarction;
Authors/Task Force Members Chairpersons, ; Thygesen K and Alpert
JS: Third universal definition of myocardial infarction. J Am Coll
Cardiol. 60:1581–1598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wiltgen M and Tilz GP: DNA microarray
analysis: Principles and clinical impact. Hematology. 12:271–287.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Horváth Z, Csuka D, Vargova K, Kovács A,
Molnár ÁA, Gulácsi-Bárdos P, Leé S, Varga L, Kiss RG, Préda I and
Füst G: Elevated C1rC1sC1inh levels independently predict
atherosclerotic coronary heart disease. Mol Immunol. 54:8–13. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takahashi M, Mori S, Shigeta S and Fujita
T: Role of MBL-associated serine protease (MASP) on activation of
the lectin complement pathway. In Adv Exp Med Biol. 598:93–104.
2007. View Article : Google Scholar
|
|
21
|
Pesonen E, Hallman M, Sarna S, Andsberg E,
Haataja R, Meri S, Persson K, Puolakkainen M, Ohlin H and Truedsson
L: Mannose-binding lectin as a risk factor for acute coronary
syndromes. Ann Med. 41:591–598. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koch A, Melbye M, Sørensen P, Homøe P,
Madsen HO, Mølbak K, Hansen CH, Andersen LH, Hahn GW and Garred P:
Acute respiratory tract infections and mannose-binding lectin
insufficiency during early childhood. JAMA. 285:1316–1321. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peterslund NA, Koch C, Jensenius JC and
Thiel S: Association between deficiency of mannose-binding lectin
and severe infections after chemotherapy. Lancet. 358:637–638.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ali YM, Lynch NJ, Haleem KS, Fujita T,
Endo Y, Hansen S, Holmskov U, Takahashi K, Stahl GL, Dudler T, et
al: The lectin pathway of complement activation is a critical
component of the innate immune response to pneumococcal infection.
PLoS Pathog. 8:e10027932012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Low HZ, Hilbrans D, Schmidt-Wolf IG and
Illges H: Enhanced CD21 expression and shedding in chronic
lymphatic leukemia: A possible pathomechanism in disease
progression. Int J Hematol. 96:350–356. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Asokan R, Banda NK, Szakonyi G, Chen XS
and Holers VM: Human complement receptor 2 (CR2/CD21) as a receptor
for DNA: Implications for its roles in the immune response and the
pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol.
53:99–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nuutila J, Jalava-Karvinen P, Hohenthal U,
Kotilainen P, Pelliniemi TT and Nikoskelainen J: Use of complement
regulators, CD35, CD46, CD55 and CD59, on leukocytes as markers for
diagnosis of viral and bacterial infections. Hum Immunol.
74:522–530. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang Y, Qiao F, Abagyan R, Hazard S and
Tomlinson S: Defining the CD59-C9 binding interaction. J Biol Chem.
281:27398–27404. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mayilyan KR: Complement genetics,
deficiencies and disease associations. Protein Cell. 3:487–496.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu G, Hu W, Shahsafaei A, Song W, Dobarro
M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA and Qin
X: Complement regulator CD59 protects against atherosclerosis by
restricting the formation of complement membrane attack complex.
Circ Re. 104:550–558. 2009. View Article : Google Scholar
|
